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ABSTRACT
As the World Trade Organization considers a proposal to waive or
otherwise address intellectual property barriers to the global response to the
COVID-19 pandemic, most of the attention given by scholars and policy
makers has been focused on patents. The original proposals by South Africa
and India, as well as the groundbreaking support of the United States,
however, explicitly applied to all forms of intellectual property. This paper
documents many instances where non-patent forms of intellectual property
create barriers to the global scale up of access to vaccines, treatments, and
the ability to contain the virus through social distancing. Addressing the full
scope of such barriers would assist the global efforts to combat COVID-19.
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INTRODUCTION
Intellectual property is a two-way street. In the general case, the
protection of exclusive rights to practice inventions and use information may
benefit social welfare through incentives to create information goods, even
where some access to those goods is curtailed. 2 But enforcement of exclusive
rights can also cut the other way, reducing innovation and causing undue
social harm through lack of access to end products. 3 Promoting access to
intellectual property, including through compulsory licenses or limitations
and exceptions to rights, becomes economically and morally justifiable in
fields where the costs of exclusion clearly outweigh its benefits. 4 There is a
growing understanding that COVID-19 vaccine patents – largely invented
through public funding and advance purchase commitments by government
– should be opened to competition in the public interest under this logic. 5
This understanding has been most prominently expressed in a proposal by
India and South Africa that the World Trade Organization suspend its

2

An “information good” is an end product “whose value is in important part constituted
by their information content.” Amy Kapczynski, The Cost of Price: Why and How to Get
Beyond Intellectual Property Internalism, 59 UCLA L. REV. 970, 995 (2012) (citing
textbooks, newspapers, medicines, art, literature and music as examples).
3
See Giovanni Dosi & Joseph Stiglitz, The Role of Intellectual Property Rights in the
Development Process, with Some Lessons from Developed Countries: An Introduction 22
(LEM Working Paper Series, No. 2013/23, Scuola Superior Sant’Anna, Laboratory of
Economics
and
Management,
2013),
https://www.econstor.eu/bitstream/10419/89516/1/771928769.pdf (on the “relations
between the regimes of IPR protection and rates of innovations”, the authors conclude that
“either the relation is not there, or if it is there that it might be a perverse one, with strong
IPR enforcement actually deterring innovative efforts.”).
4
See Sean Flynn, Aidan Hollis, & Michael Palmedo, An Economic Justification for
Open Access to Essential Medicine Patents in Developing Countries. 37 JOURNAL OF LAW,
MEDICINE AND ETHICS (2009) (explaining the economic case and concluding that markets
for essential medicines in developing countries is a field where IP systematically produces
far higher social costs from reduced access than benefits from incentives to produce new
treatments); Thomas W. Pogge, Human Rights and Global Health: A Research Program, 36
(1-2) METAPHILOSOPHY 182 (2005) (explaining the moral case). Cf Jessica Litman, The
Public Domain, 39 EMORY L. J. 965, 968 (1990) (describing the public domain of
unprotected information resources as best “understood not as the realm of material that is
undeserving of protection, but as a device that permits the rest of the system to work by
leaving the raw material of authorship available for authors to use”).
5
See, e.g., Dr. Tedros Adhanom Ghebreyesus, Waive Covid vaccine patents to put world
on war footing, WORLD HEALTH ORGANIZATION (Mar, 7, 2021), https://www.who.int/newsroom/commentaries/detail/waive-covid-vaccine-patents-to-put-world-on-war-footing;
Stephen Buranyi, The world is desperate for more Covid vaccines - patents shouldn’t get in
GUARDIAN
(Apr.
24,
2021,
06:00
EDT),
the
way,
THE
https://www.theguardian.com/commentisfree/2021/apr/24/covid-vaccines-patentspharmaceutical-companies-secrecy;
WCL.AMERICAN.EDU/PIJIP
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intellectual property rules for COVID-19 measures. 6
The TRIPS waiver proposal is not limited to patents on vaccines. The
proposal called for a suspension of WTO rules on all forms of intellectual
property needed for a broad range of COVID-19 response measures,
including for “vaccination,” “treatment,” and “containment.” 7 Some
commentators and WTO negotiators have proposed limiting the scope of the
instrument to vaccine patents. 8 There is little published research examining
the non-patent barriers to COVID-19 to the full range of responses addressed
by the original TRIPS waiver proposal. 9 This paper fills that gap by
summarizing literature in news and other sources describing potential nonpatent intellectual property barriers to public health responses to the COVID19 pandemic.
We conclude that non-patent barriers to COVID-19 responses are myriad
and important. Access to copyrighted works, including software, is essential
for COVID-19 related research, manufacture and repair of medical devices
and equipment, manufacture of mRNA vaccines, and for the social distancing
in education and other spheres required to contain outbreaks. Access to trade
secrets and undisclosed “know how” are essential to achieving distributed
production of vaccines, medicines and devices, even when patent protection
is absent. International intellectual property law contains flexibilities that can
be interpreted to permit emergency action by countries to overcome these
barriers. We suggest ways that international organizations, including but not
limited to the WTO, could clarify, and promote these flexibilities to aid
COVID-19 responses.
This article progresses in three parts. In Parts I and II, we describe

6
Council for Trade-Related Aspects of Intellectual Property Rights, Waiver from
Certain Provisions of the TRIPS Agreement for the Prevention, Containment and Treatment
of
COVID-19,
WTO
Doc.
IP/C/W/669/Rev.1
(May
25,
2021),
https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669R1.pdf&Open
=True [hereinafter “Revised TRIPS Waiver Proposal”].
7
Council for Trade-Related Aspects of Intellectual Property Rights, Waiver from
Certain Provisions of the TRIPS Agreement for the Prevention, Containment and Treatment
of
COVID-19,
WTO
Doc.
IP/C/W/669
(Oct.
2,
2020)
https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&Open=T
rue
8
See Gary Winslett, A Compromise Moratorium, R STREET (March 2, 2021),
https://www.rstreet.org/2021/03/02/a-compromise-moratorium/. The popular press often
assumes this narrowing even where it has not occurred, referring to the WTO proposal as a
“patent waiver.” See, Editorial, A patent waiver on COVID vaccines is right and fair,
NATURE (May 25, 2021); Emma Farge, Even after U.S. shift, opponents resist COVID-19
(May
31,
2021,
5:48
PM),
vaccine
patent
waiver,
REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/even-after-us-shiftopponents-resist-covid-19-vaccine-patent-waiver-2021-05-31/
9
For a useful exception, see Doris Estelle Long, The Overlooked Role of Copyright in
Securing Vaccine Distribution Equity, TRADERX REPORT (Sept. 6, 2021),
https://www.traderxreport.com/covid-19/the-overlooked-role-of-copyright-in-securingvaccine-distribution-equity/
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evidence that access to copyrights and trade secrets, respectively, are needed
to respond to the COVID pandemic. 10 Part III defines opportunities for
international action – including opportunities beyond the current TRIPS
waiver discussion – that could clarify the international policy flexibility
needed to address these barriers. This information may be useful to
international policy makers in the WTO, WIPO and other multilateral
agencies exploring avenues for international intellectual property policy to
contribute to the response to the COVID pandemic.
I.

THE NEED FOR USES OF COPYRIGHTED WORKS TO COMBAT COVID

Access to copyrighted works, including software, is essential for COVID19 related research, for the provision of vaccines and treatment, and for
containing the spread of the virus through social distancing.
A. Research
Advanced research methodologies using text and data mining has been
instrumental in identifying and tracking COVID-19 as well as in identifying
candidates for vaccines and other treatments.
1. Access to Scientific Literature
Researchers cannot contribute to COVID-19 responses if they cannot
access the scientific literature they need to conduct their work. A global
survey recently found that about 20% of researchers globally, and over 30%
of researchers in South America (where copyright exceptions are the most
limited), report that COVID has “completely” altered or halted their work. 11
Researchers and governments have called for voluntary efforts by
publishers to release access to research materials and data to aid the global
fight against the pandemic. 12 Many publishers have responded by making

10

The obligations to “promote” and “provide” access to medicines are part of the duties
of states and international organizations to fulfil the international right to health. See U.N.
Committee on Economic, Social and Cultural Rights, General Comment No. 14: The Right
to the Highest Attainable Standard of Health (Art. 12 of the International Covenant on
Economic, Social and Cultural Rights), adopted at the 22nd Session of the Committee on
Economic, Social and Cultural Rights, U.N. Doc. E/C.12/2000/4 (Geneva, Aug. 11, 2000).
11
Chantelle Rijs & Frederick Fenter, The Academic Response To Covid-19, Fʀᴏɴᴛɪᴇʀs,
7 (Oct. 28, 2020) (summarizing the results of a two month long survey of academics from
several countries).
12
See Letter by National Science and Technology Advisors in select Countries to the
Members of the
Scholarly Publishing Community (Mar. 13, 2020),
https://wellcome.org/sites/default/files/covid19-open-access-letter.pdf (calling for action to
help scientists “keep up with the rapidly growing body of literature and identify trends and
relevant information in efforts to characterize this novel virus and address the associated
global health crisis”); European Commission, European Commission signs letter to scholarly
publishing community in the fight against coronavirus (Mar. 31, 2020),
https://ec.europa.eu/info/news/european-commission-signs-letter-scholarly-publishingcommunity-fight-against-coronavirus-2020-mar-30_en; White House Office of Science and
WCL.AMERICAN.EDU/PIJIP
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publications relevant to COVID-19 freely available. 13 The number of articles
being made available through open licensed platforms is diminishing over
time, however, indicating a potential need for further action to ensure that
researchers have access to literature and data. 14
2. Text and Data Mining (TDM)
Text and data mining – in which computational processes are used to
derive data from or about a corpus of works 15 -- has been central to many
research breakthroughs regarding COVID-19. The outbreak was discovered
by a Canadian text and datamining company, BlueDot, which tracks
emerging health threats by analyzing “a variety of information sources,
including chomping through 100,000 news reports in 65 languages a day.” 16
TDM projects also mine scientific publications and other forms of data about
the coronavirus family to aid vaccine research and development. 17
Many of the materials used for COVID-related data mining projects are
covered by copyright, including the news articles mined by BlueDot and the
scientific articles mined by vaccine researchers. Less than 25% of the world’s
copyright laws fully permit even non-commercial text and datamining
research. 18 The lack of copyright permission for such uses can block research

Technology Policy, Call to Action to the Tech Community on New Machine Readable
COVID-19 Dataset, Trump White House Archives (Mar. 16, 2020),
https://trumpwhitehouse.archives.gov/briefings-statements/call-action-tech-communitynew-machine-readable-covid-19-dataset/.
13
Press Release, Publishers make coronavirus (COVID-19) content freely available and
reusable, WELLCOME (Mar. 15, 2020), https://wellcome.org/press-release/publishers-makecoronavirus-covid-19-content-freely-available-and-reusable.
14
See Jeffrey Brainard, No revolution: COVID-19 boosted open access, but preprints
are only a fraction of pandemic papers, SCIENCE (Sep. 8, 2021, 2:45 PM),
https://www.science.org/content/article/no-revolution-covid-19-boosted-open-accesspreprints-are-only-fraction-pandemic-papers (reporting that 77% of COVID-19 papers were
free to read in early September 2021 – down from a high of 85% in May 2020).
15
Sean Flynn et al., Implementing User Rights for Research in the Field of Artificial
Intelligence: A Call for International Action 42 (7) EIPR 393 (2020).
16
Mark Prosser, How AI Helped Predict the Coronavirus Outbreak Before it Happened,
SINGULARITY HUB (Feb. 05, 2020), https://singularityhub.com/2020/02/05/how-ai-helpedpredict-the-coronavirus-outbreak-before-it-happened/; Corey Stieg, How this Canadian
Start-Up Spotted Coronavirus Before Everyone Else Knew About it, CNBC: MAKE IT (Mar.
6, 2020, 1:40 PM), https://www.cnbc.com/2020/03/03/bluedot-used-artificial-intelligenceto-predict-coronavirus-spread.html .
17
See Will Knight, Researchers Will Deploy AI to Better Understand Coronavirus,
WIRED, (Mar. 17, 2020, 08:00 AM), https://www.wired.com/story/researchers-deploy-aibetter-understand-coronavirus/; Carrie Arnold, How Computational Immunology Changed
the Face of COVID-19 Vaccine Development, NATURE: NATURE MEDICINE (Jul. 15, 2020),
https://www.nature.com/articles/d41591-020-00027-9; Emily Waltz, What AI Can-and
Can’t Do in the Race for a Coronavirus Vaccine, IEEE: IEEE SPECTRUM (Sep. 29, 2020)
(describing how “[m]achine-learning systems and computational analyses have played an
important role in the vaccine quest,” including “helping researchers understand the virus and
its structure, and predict which of its components will provoke an immune response”).
18
Sean Flynn, et. al., Comparative Law on Copyright Exceptions for Research (PIJIP
FLYNN, NKRUMAH, AND SCHIRRU
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and publication. 19 In July 2021, for example, a group of researchers in Canada
and India were forced to retract a paper on vaccine hesitancy and Covid-19
because they lacked a license to mine a database of news articles used in the
study. 20
B. Treatment
Access to copyrighted materials is necessary to create and repair many
medical devices needed to treat COVID-19. Manufacturers have used
copyright claims to prevent such repair and replacement of critical
equipment.
1. Algorithms for mRNA Vaccines
Patents are not the only intellectual property barrier to the production of
the leading mRNA vaccines. The creation of mRNA vaccines requires
identification of “MicroRNAs (miRNAs)” – “small non-coding RNA that
target gene expression at post-transcriptional level.” 21 “To understand the
molecular basis of miRNA regulation, it is essential to identify reliable
miRNA target mRNAs and miRNA–mRNA functional networks,” which
relies on several widely used computational algorithms and tools. 22 Such
tools may be subject to copyright or other forms of data protection in many
countries. 23
Working Paper) (forthcoming 2021). See also Part III, below.
19
On the lawfulness of text and data mining under U.S. copyright law, see Michael W.
Carroll, Copyright and the Progress of Science: Why Text and Data Mining is Lawful, 53
U.C. DAVIS L. REV. 893 (2019)
20
‘A very unfortunate event’: Paper on COVID-19 vaccine hesitancy retracted, RETRACTION
WATCH , https://retractionwatch.com/2021/07/30/a-very-unfortunate-event-paper-on-covid19-vaccine-hesitancy-retracted/ (last visited, Oct. 6, 2021)
21
Rishav Ray & Priyanka Pandey, Surveying computational algorithms for
identification of miRNA–mRNA regulatory modules, 60 THE NUCLEUS 165 (2017)
22
Id.
23
See Clark D. Asay, Artificial Stupidity 61 WILLIAM & MARY L. REV. 1187, 1241
(BYU Law Research Paper No. 20-03. 2020) (“Finally, the fact remains that for many AI
innovations, patenting remains a suboptimal intellectual property strategy because of patent
law’s disclosure requirements.334 Trade secrecy, in contrast, provides some legal
protections without the need to share with the world a party’s AI details.335 And though
trade secrecy may provide such advantages, it is also typically associated with higher
transaction costs as parties undertake extensive, costly measures to guard that secrecy.336”)
(footnotes omitted); Guido Noto La Diega. Against the Dehumanisation of Decision-Making
– Algorithmic Decisions at the Crossroads of Intellectual Property, Data Protection, and
Freedom of Information, 9 JIPITEC 3, 12 (2018) (“Even though there are many open-source
machine learning frameworks (e.g. Apache Singa, Shogun, and TensorFlow), most AI
algorithms are proprietary… i.e. covered primarily by trade secrets,97 … Under the new
Trade Secrets Directive,99 algorithms can be covered by trade secrets because they are not
generally known or easily accessible and they have commercial value.100 This is true as
long as the person who has control of the algorithm takes steps to keep it secret.101”
(footnotes omitted); See also FIVEIPOFFICES (IP5). Report from the IP5 expert round table
on artificial intelligence 2 (Oct. 31, 2018) (“Algorithms as such may not be eligible for patent
protection. However, if the underlying algorithm is claimed as a series of concrete procedural
WCL.AMERICAN.EDU/PIJIP
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2. Marketing Labels and Inserts
Even if a competing vaccine or treatment is lawfully produced with
respect to patent law, there are opportunities for companies to use copyrights
to halt or delay generic marketing. The issue arises because labels and
package inserts – which convey information often required by regulators –
may be considered protected by copyright in some countries. There is a
history of pharmaceutical companies making such claims (ultimately
ineffectively) in the U.S. 24 A recent report by WTO and WIPO explained that
the practice of using copyrights to block generic production continues in
other countries. 25
3. Repair Manuals
Copyright is frequently used to block competition in the repair of medical
devices. 26 One tool companies use to block unlicensed repairs is to prohibit
the use and sharing of copyrighted repair manuals. In a recent example
reported by the Electronic Frontier Foundation (EFF), the maker of
sterilization-related devices demanded that their products’ documentation be
taken down from an open access repository of repair information based on

steps solving a technical problem or is incorporated into a practical application, it can be
eligible
for
patent
protection.”)
https://www.fiveipoffices.org/wcm/connect/fiveipoffices/5e2c753c-54ff-4c38-861c9c7b896b2d44/IP5+roundtable+on+AI_report_22052019.pdf?MOD=AJPERES&CVID=
IP5 (2018, p. 2). But see Andrew C. Michaels, Abstract Innovation, Virtual Ideas, and
Artificial Legal Thought, 14 JOURNAL OF BUSINESS & TECHNOLOGY LAW 1, 11 (2018) “A
pure algorithm for example, even if inventive or “newly discovered,” is an abstract idea
ineligible for patent protection.48” (footnote omitted).
24
See Zvi S. Rosen, Product Labels and the Origins of Copyright Examination,
(MOSTLY) IP HISTORY (May 23, 2017) http://www.zvirosen.com/2017/05/23/productlabels-and-the-origins-of-copyright-examination/ (describing the U.S. history of
manufactures attempting to use copyright claims to gain marketing exclusivity); Roseann B.
Termini & Amy Miele, Copyright and Trademark Issues in the Pharmaceutical Industry:
Generic Compliance or Brand Drug Imitating: 'Copycat or Compliance', PENNSYLVANIA
BAR ASSOCIATION QUARTERLY (Jan. 2013)(same). See e.g. SmithKline Beecham Consumer
Healthcare, L.P. v. Watson Pharm, Inc., 211 F.3d 21 (2d Cir. 2000), cert. denied, 531 U.S.
872 (2000) (rejecting copyright claims to label information as grounds for restricting
marketing of generic).
25
WHO/WIPO/WTO, Promoting Access to Medical Technologies and Innovation:
Intersections between public health, intellectual property and trade, 87 (2nd ed. 2020)
(explaining that “courts have sometimes found that generic pharmaceutical producers cannot
reproduce for their own products direct copies of the original expressions contained in
package inserts of the first producer of the product,” citing litigation brought by
pharmaceutical companies South Africa and Australia).
26
Jason Koebler, Hospitals Need to Repair Ventilators. Manufacturers Are Making That
MOTHERBOARD
(Mar.
18,
2020,
11:15
PM),
Impossible,
VICE:
https://www.vice.com/en/article/wxekgx/hospitals-need-to-repair-ventilatorsmanufacturers-are-making-that-impossible (describing how manufacturers have cemented a
“repair monopoly … by lobbying against legislation that would make it easier to repair
machines, keeping access to repair guides out of the hands of independent repair
professionals, and using software controls to limit who can perform repairs”).
FLYNN, NKRUMAH, AND SCHIRRU
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copyright claims over that documentation. 27
4. 3D Printing
Copyright is complicating the use of 3D printing technology to print
replacement parts for ventilators and other devices. Copyright can cover the
3D digital file needed to print objects, and copyright or design rights may
cover the form and shape of the printed object. 28 In one recent example,
copyrighted files and manuals needed to print ventilator valves were denied
by their manufactures to Italian researchers attempting to use 3D printing to
fill critical parts shortages during the height of that country’s initial
outbreak. 29
5. Software Enabled Devices
Ventilators and other medical devices have copyrighted software
integrated into their operation. 30 Accordingly, to repair such equipment
copyright permission to access the software and bypass technological
protection measures may be required. 31
The right to access software to make repairs to ventilators and other
devices was a core request of 326 hospital repair experts in a letter to the U.S.
Congress. 32 The advocacy led to the introduction of the Critical Medical
27

Kit Walsh, Medical Device Repair Again Threatened With Copyright Claims,
FRONTIER
FOUNDATION
(June
11,
2020),
ELECTRONIC
https://www.eff.org/deeplinks/2020/06/medical-device-repair-again-threatened-copyrightclaims; (describing EFF’s defense of the contributions of manuals to the open access Medical
Device Repair Database posted to the website iFixit); Letter from Russell S. Wheatley, Steris
Corp. Chief IP Counsel to Kyle, Wiens, iFixit, CEO, ELECTRONIC FRONTIER FOUNDATION
(May 26, 2020), https://www.eff.org/document/letter-steris-ifixit-5-16-2020.
28
Elsa Malaty & Guilda Rostama, 3D Printing and IP Law, WIPO MAGAZINE (Feb.
2017), https://www.wipo.int/wipo_magazine/en/2017/01/article_0006.html
29
See Urian B., 3D Printer Saves Lives of Italian Coronavirus Patients As Hospitals
Run Out of Ventilators! Here’s How, TECH TIMES (Mar. 16, 2020, 11:03 PM),
https://www.techtimes.com/articles/248085/20200316/3d-printer-saves-lives-italiancoronavirus-patients-hospitals-run-out-ventilators.htm; Faye Brown, Firm ‘refuses to give
blueprint’ for coronavirus equipment that could save lives, METRO NEWS (Mar. 16, 2020,
12:06
PM),
https://metro.co.uk/2020/03/16/firm-refuses-give-blueprint-coronavirusequipment-save-lives-12403815/; Urian B., Maker of $11,000 Ventilator Valves Threatens
to Sue Volunteers Using $1 3D-Printed Replicas That Just Saved 10 Coronavirus Patients!,
TIMES
(Mar.
17,
2020,
10:03
PM),
TECH
https://www.techtimes.com/articles/248121/20200317/maker-ventilator-valves-threatenssue-volunteers-using-3d-printed-coronavirus.htm
30
Example of software used in ventilator, see Puritan Bennett Ventilator Software,
https://www.medtronic.com/covidien/en-us/products/mechanicalMEDTRONIC,
ventilation/software.html (last visited Oct. 06, 2021)
31
See generally Leah Chan Grinvald & Ofer Tur-Sinai, Intellectual Property Law and
the Right to Repair, 88 FORDHAM L. REV. 63, 104 (2019) (noting that under US law
“[c]onsumers cannot disable the digital lock without being liable …, even if the purpose for
such hack was to diagnose, maintain, or repair the product”).
32
Nathan Proctor, Hospital Repair Professionals: Just Let Us Fix Life-saving Devices
Including Ventilators, U.S. PIRG (May 18, 2020), https://uspirg.org/news/usp/hospitalWCL.AMERICAN.EDU/PIJIP
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Infrastructure Right to Repair Act of 2020, eliminating “liability under
federal copyright law for creating an incidental copy of service materials or
for breaking a digital lock during the course of equipment repair in response
to COVID-19”. 33 That law has not passed, however, leaving care-givers in
the U.S., as in many other countries, without the legal tools they need to repair
software enabled devices. 34
6. Personal Protective Equipment (PPE) Standards
To address shortages of personal protective equipment (PPE), the
European Committee for Standardization and the European Committee for
Electrotechnical Standardization opened access to its copyrighted standards
for production of PPEs. 35 Ordinarily, the standards need to be licensed from
the standard setting organizations due to copyright. 36 The European
Commission explained that “the derogation from this business model is a
strong European response, based on a sense of social responsibility and
solidarity, to address the shortage problem of protective equipment deriving
from the Covid-19 epidemics.” 37
C. Containment
The final and perhaps most obvious example of the need for access to
copyright to battle the COVID-19 pandemic is in promoting social
distancing. 38 For the majority of the world’s population, the only way to
repair-professionals-just-let-us-fix-life-saving-devices-including-ventilators;
33
Press Release, Wyden and Clarke Introduce Bill to Eliminate Barriers to Fixing
Critical Medical Equipment During the Pandemic, RON WYDEN U.S. SENATOR FOR OREGON
(Aug. 6, 2020), https://www.wyden.senate.gov/news/press-releases/wyden-and-clarkeintroduce-bill-to-eliminate-barriers-to-fixing-critical-medical-equipment-during-thepandemic- (quoting Senator Wyden that “it is just common sense to say that qualified
technicians should be allowed to make emergency repairs or do preventative maintenance,
and not have their hands tied by overly restrictive contracts and copyright laws, until this
crisis is over”),
34
There are a small number of voluntary measures that seek to overcome copyright
barriers to the use of software. The government of Singapore publicly shared copyrighted
software relating to its contact-tracing app to assist contact-tracing strategies by public health
authorities worldwide. See Hariz Baharundin, Coronavirus: S'pore Government to make its
contact-tracing app freely available to developers worldwide, THE STRAITS TIMES (Mar. 23,
2020, 5:58 PM SGT), https://www.straitstimes.com/singapore/coronavirus-sporegovernment-to-make-its-contact-tracing-app-freely-available-to; BLUETRACE PROTOCOL,
https://bluetrace.io/ (last visited Oct. 6, 2021). Some software providers have included their
products
within
the
Open
COVID
Pledge.
OPEN COVID PLEDGE,
https://opencovidpledge.org/partner-ip/ (last visited Oct. 06 021)
35
Press Release, European Commission, Coronavirus: European standards for medical
supplies made freely available to facilitate increase of production (Mar. 20, 2020),
https://ec.europa.eu/commission/presscorner/detail/en/ip_20_502
36
Id.
37
Id.
38
See Coronavirus disease (COVID-19) advice for the public, World Health
Organization, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advicefor-public (last visited Sep 30, 2021)
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prevent the virus is through social distancing. Promoting such distancing
while protecting needed access to educational, research and cultural heritage
materials requires rights to communicate copyrighted works over the internet.
1. Institutional closures
To promote social distancing, essential public institutions – including
schools, universities, libraries, archives, and museums – have closed in
countries across the world. UNESCO reports that COVID-19 has “created
the largest disruption of education systems in history,” “affecting nearly 1.6
billion learners in more than 190 countries,” “94 per cent of the world’s
student population,” and “up to 99 per cent” of students in low and lowermiddle income countries. 39
Copyright laws often separately protect a right of “communication” or
“making available” of works through digital platforms that is required to
share materials over computer networks. Most education and research
exceptions to copyright only cover the right of reproduction, and many are
limited to specific uses such as “in the classroom” or “on the premises” of a
library. 40
2. The Inadequacy of Voluntary Licensing
There have not been wide-scale voluntary measures to permit digital uses
of educational or research materials as there has been with respect to COVIDrelated scientific articles. For example, only a small number of publishers
have permitted uses of any of their works to conduct children’s story-time
readings online. 41 Many publishers and collective management organizations
39
U.N., Policy Brief: Education during COVID-19 and beyond, 2 (Aug. 2020). See also
1.3 Billion Learners are Still Affected by School or University Closures, as Educational
Institutions Start Reopening Around the World, Says UNESCO, UNESCO (Apr. 29, 2020),
https://en.unesco.org/news/13-billion-learners-are-still-affected-school-university-closureseducational-institutions,; COVID-19 Impact on Education, UNESCO (last visited Oct. 06,
2021) https://en.unesco.org/covid19/educationresponse (global monitoring of school
closures caused by COVID-19).
40
See part III, below.
41
See Access Copyright, Read Aloud Canadian Books Guidelines of Use,
accesscopyright.ca/media/1438/read-aloud-canadian-books-program-guidelines-of-use.pdf
(last visited Oct. 06, 2021) (announcing a special license for their “Read Aloud Canadian
Books Program” that covers only select books from participating publishers); Carys J. Craig
& Bob Tarantino, “An Hundred Stories in Ten Days”: COVID-19 Lessons for Culture,
Learning and Copyright Law 62 (Joint PIJIP/TLS Research Paper Series No. 10-2020)
(reviewing voluntary pledges for educational uses and finding it “quickly evident that many
titles in their catalogues are unavailable, certain publishers have made nothing newly
available, and access to free volumes is stringently limited to particular audiences and for a
specified time”); Virtual Storytimes Aotearoa, LIANZA, https://lianza.org.nz/covid19/virtual-storytimes/ (last visited Oct. 06, 2021) (listing “Public libraries [that] hosted
nearly 750 virtual storytimes during the COVID-19 pandemic lockdown in late March”);
Denise R. Nicholson, How SA’s Copyright Bill Would Benefit Citizens During COVID, EIFL
(Nov. 13, 2020) (reporting that few temporary waivers or reductions in copying fees were
offered by CMOs in South Africa for COVID-related uses), https://www.eifl.net/blogs/how-
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are working in the opposite direction, explicitly demanding additional
licenses for online uses of works. 42
In sum, many essential activities needed to combat COVID-19, including
research, vaccines and treatments, and promoting social distancing, require
access to copyrighted works. But the non-patent barriers to COVID-19
responses do not end there. As the next section shows, access to trade secrets
and know how are also essential to the production of vaccines and treatments.
II.

THE NEED FOR ACCESS TO TRADE SECRETS AND KNOW HOW

Access to patents provides only a part of what a local producer needs to
produce a vaccine, medicine or treatment device. Patents require the recipient
to disclose the invention being protected. But patentees are not required to
disclose everything they know to most efficiently reproduce their invention. 43
If the world is going to achieve a rapid scale up of production capacity, the
sharing of trade secrets and know how must be accomplished.
A. Trade Secrets on Medicines and Vaccines
Undisclosed knowledge can be a significant barrier to entry for new firms,
even where authorizations to use patented technology exists. 44 Thus,

sas-copyright-bill-would-benefit-citizens-during-covid
42
For example, Access Copyright, a reproduction rights collective in Canada, published
an article warning organizations: “your co-workers are probably sharing content without
permission from the copyright owners,” threatening “legal action for copyright
infringement” without an extended license form the organization including online uses.
COPYRIGHT,
Working
from
home
and
copyright,
ACCESS
https://www.accesscopyright.ca/businesses/working-from-home-and-copyright/ (last visited
Jan. 15, 2021) (“During this pandemic and at any other time, our team is ready to meet your
needs and offer you a range of solutions tailored to how you work”). See also Nicholson,
supra note 38 (describing a university lecturer in South Africa who was denied permission
from a publisher and the local collective management organization to place sections of an ebook version of a textbook on her institution’s password-protected e-learning platform for
the specific class for a period of 6 weeks).
43
See Christopher Garrison, What is the ‘know-how gap’ problem and how might it
impact scaling up production of Covid-19 related diagnostics, therapies and vaccines?,
MEDICINES LAW & POLICY (Dec. 16, 2020) (describing that, even in countries that require
disclosure of the best mode for producing an invention, much of the practical information
required to efficiently compete with the original producer may be protected by trade secret
or otherwise withheld), https://medicineslawandpolicy.org/2020/12/what-is-the-know-howgap-problem-and-how-might-it-impact-scaling-up-production-of-covid-19-relateddiagnostics-therapies-and-vaccines/.
44
Karl F. Jorda, Trade Secrets and Trade-Secret Licensing, in INTELLECTUAL PROPERTY
MANAGEMENT IN HEALTH AND AGRICULTURAL INNOVATION: A HANDBOOK OF BEST
PRACTICES Chapter 1043, 1051 (A. Krattiger, R.T. Mahoney, L. Nelsen, et. al. eds. 2007)
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. (explaining that “as a practical matter,
licenses under patents without access to associated or collateral know-how are often not
enough for taking advantage of the patented technology commercially … because patents
rarely
disclose
the
ultimate
scaled-up
commercial
embodiments”),
http://www.iphandbook.org/handbook/ch11/p05/.
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Moderna, the maker of one mRNA COVID-19 vaccine, explained to its
investors that it anticipates ongoing market exclusivity even in the face of its
public pledge not to enforce its patents. 45 “We also rely to a certain extent on
trade secrets, know-how, and technology, which are not protected by patents,
to maintain our competitive position,” it explained in 2020 Quarterly Report
in 2020. 46 Similarly, access to medicine advocates have criticized Roche for
releasing patents to the medicine Tocilizumab, 47 which is recommended by
the World Health Organization (WHO) for treating severe COVID-19, 48 in
part because Roche did not include “open, transparent and unrestricted
transfer of … its regulatory dossier and any other manufacturing information,
which is critical for immediate scale-up of production by other
manufacturers.” 49
B. Trade Secrets on Tests and Devices
Lack of access to trade secrets has impeded access to COVID testing in
several countries. For example, laboratories in South Africa were cut off from
a supply of needed reagents for a COVID test, and were prevented from
making the materials themselves because of a refusal of the manufacturer to
share its trade secret recipes. 50 A refusal to license trade secrets to another
45
Press Release. Statement by Moderna on Intellectual Property Matters during the
COVID-19 Pandemic, MODERNA (Oct. 8, 2020, 6:39 AM) (explaining that its public pledge
does not extend to know how), https://investors.modernatx.com/news-releases/news-releasedetails/statement-moderna-intellectual-property-matters-during-covid-19.
46
Moderna, Inc., Quarterly Report for the quarterly period ended June 30, 2020 (Form
10-Q) at 93 (Aug. 06, 2020) (noting that “[i]f any trade secret, know-how, or other
technology not protected by a patent were to be disclosed to or independently developed by
a competitor, our business and financial condition could be materially adversely affected”).
https://www.sec.gov/Archives/edgar/data/1682852/000168285220000017/mrna20200630.htm
47
Kerry Cullinan, Roche Suspends Patents on Tocilizumab in LMICs after WHO
Recommends it as Treatment for Severe COVID-19, HEALTH POLICY WATCH (July 8, 2021),
https://healthpolicy-watch.news/roche-suspends-patents-on-tocilizumab-for-lmics-afterwho-recommends-it-as-treatment-for-severe-covid/.
48
WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and
urges producers to join efforts to rapidly increase access, WORLD HEALTH ORGANIZATION
(July 6, 2021), https://www.who.int/news/item/06-07-2021-who-recommends-life-savinginterleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-torapidly-increase-access.
49
Press Release, MSF Response to Roche’s statement on access to tocilizumab,
MEDICINS SANS FRONTIERES ACCESS CAMPAIGN (July 9, 2021), https://msfaccess.org/msfresponse-roches-statement-access-tocilizumab.
50
Catherine Tomlinson, COVID-19: Behind SA’s shortages of test materials,
SPOTLIGHT (May 5, 2020), https://www.spotlightnsp.co.za/2020/05/05/covid-19-behindsas-shortages-of-test-materials/. It was only after threats of investigation for anti-competitive
conduct by the European Commission that Roche eventually took steps to release its recipe.
See Eelke Van Ark & Jan-Hein Strop, Roche releases recipe after European Commission
considers intervention due to lack of coronavirus tests, FOLLOW THE MONEY (March 27,
2020),
https://www.ftm.nl/artikelen/roche-releases-recipe-after-public-pressure-whileeuropean-commission-considers-intervention-due-to-coronavirus-test; Ed Silverman, Roche
backpedals and agrees to provide a solution for COVID-19 tests in the Netherlands, STAT
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COVID-19 test used frequently in developing countries has been blamed by
access to medicine advocates for perceived price gauging and supply
constraints. 51
Ultimately, it is clear that addressing patent rights alone will not solve the
full range of intellectual property barriers to vaccines, treatments and
containment measures needed to defeat COVID-19. International action to
clarify flexibilities in the international system to respond to non-patent
barriers are also needed. Some of the targets for such clarification are
described in the next Part.
III.

CLARIFICATIONS NEEDED IN INTERNATIONAL LAW

International intellectual property law, including that contained in the
WTO TRIPS Agreement, could be usefully clarified in its application to nonpatent barriers responses to the COVID-19 pandemic. The TRIPS waiver
proposal, which would constitute a subsequent agreement between the same
parties of the most important treaty mandating minimum standards for
copyrights and trade secrets, is one key opportunity for such clarification. 52
This part discusses the role of other agencies, including the World Intellectual
Property Organization, as well.
A. Emergency Uses of Copyrighted Works
As described below, most countries do not provide copyright exceptions
for emergency uses during COVID. There is accordingly a need to clarify the
authority under international law to take emergency action to authorize
certain uses of protected works during COVID, at least in an interim period
where laws are amended to provide more adequate exceptions.
1. Lack of Adequate Exceptions for COVID-19 Uses
Copyright laws around the world fail to provide the limitations and
exceptions needed to permit critical research, learning and health related
measures needed to respond to COVID. As shown in the figures below,
research by American University’s Program on Information Justice and

(Mar. 27, 2020), https://www.statnews.com/pharmalot/2020/03/27/roche-covid19coronavirus-netherlands/.
51
See Local Diagnostics to meet Local Health Needs, MEDECINS SANS FRONTIERES
ACCESS CAMPAIGN, at 7, 9 (Jul. 08, 2021), https://msfaccess.org/improve-local-productiondiagnostics (describing access to know-how as “especially important for complicated closed
diagnostics systems like Cepheid’s automated, cartridge-based GeneXpert tests,” only 15%
of which are dedicated to supply of developing countries); Press Release, Diagnostic
company Cepheid charging four times more than it should for COVID-19 tests, MEDECINS
SANS FRONTIERES (Jul. 28, 2020), https://www.msf.org/diagnostic-company-cepheidcharging-more-it-should-covid-19-tests (describing price gauging).
52
See United Nations Vienna Convention on the Law of Treaties, art. 31, May 23, 1969,
I-18232, 1155 UNTS 331 (providing rules of interpretation of treaties and the role of
subsequent agreements and practices).
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Intellectual Property has categorized the world’s copyright exceptions for
research into three categories. Only the countries labeled green in the figures
have sufficiently broad copyright exceptions to permit TDM research (Figure
1) or online education (Figure 2). While there are several U.S. state bills
under discussion, there is not as much notice from other countries about the
enactment of legislation on explicit rights to use works for the purpose of
device repair. 53 On the contrary, several intellectual property regimes may
impose significant obstacles to the right to repair. 54 Our review did not find
a single copyright law with an express exception for uses needed to protect
public health.

53

See Daniel Moore, You Gotta Fight for Your Right to Repair: The Digital Millennium
Copyright Act's Effect on Right-to-Repair Legislation, 6 TEX. A&M L. REV. 509, 515 (2019)
(“Since 2015, states have responded to consumers' lack of freedom to choose how to fix their
devices by trying to enact right-to-repair laws. These laws require manufacturers to offer
repair instructions and parts to independent repair technicians. During the legislative sessions
following the 2016 elections, almost half of the country's state legislatures considered rightto-repair laws.”)(footnotes omitted). See also S. Kyle Montello, The Right to Repair and the
Corporate Stranglehold over the Consumer: Profits over People, 22 TUL. J. TECH. & INTELL.
PROP. 165 (2020) (commenting that “Right to repair bills are also being considered in Canada
and the European Union (EU).”)(footnote omitted)
54
Aaron Perzanowski, Consumer Perceptions of the Right to Repair, 96 IND. L.J. 361,
377-378, 394 (2021) (commenting on the obstacles for the enactment of bills on right to
repair imposed by “anti-repair” lobby, which uses IPR-based arguments and goes against
costumers expectations on their rights); Leah Chan Grinvald & Ofer Tur-Sinai, Intellectual
Property Law and the Right to Repair, 88 FORDHAM L. REV. 63, 128 (2019) (“from a
doctrinal point of view, this Article's analysis points out that the concept of a right to repair
and the proposed state legislation that seeks to secure it are not accommodated by the United
States' far-reaching intellectual property regime.” ). See also Nicholas A. Mirr, Defending
the Right to Repair: An Argument for Federal Legislation Guaranteeing the Right to Repair,
105 IOWA L. REV. 2393, 2415 (2020) (arguing that “[t]he existing framework of copyright
law is thus insufficient to properly address the demands of the right to repair movement.135”)
(footnote omitted)
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Figure 1

Figure 2

The lack of adequate exceptions in copyright legislation raises the
question under international law whether countries can take non-legislative
measures to permit uses of copyrighted works during an emergency. One
possible source of such authorization can be found in Article 17 of the Berne
Convention.
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2. Need for Clarification of the Emergency Use Authorization in Berne
Article 17
The Berne Convention and related copyright treaties make it clear that
countries may legislate upon limitations and exceptions. 55 As shown in the
figures above, a minority of countries have used that authority to permit uses
of copyrighted works for research, online education, hardware repair, and for
other essential uses to combat COVID-19. But for those that do not yet have
such rights, legislative processes may not be sufficiently speedy to authorize
uses needed immediately. Thus the question occurs whether the international
treaty architecture permits more immediate administrative action to extend
exceptions in an emergency. 56
Authorization for emergency administrative action to overcome
copyright barriers in the case of a necessity is contained in Article 17 of the
Berne Convention:
Article 17
The provisions of this Convention cannot in any way affect the right
of the Government of each country of the Union to permit, to control,
or to prohibit, by legislation or regulation, the circulation,
presentation, or exhibition of any work or production in regard to
which the competent authority may find it necessary to exercise that
right.
It is common for commentators to point out that the main purpose of
Article 17 was to allow countries to censor copyrighted articles, and that it
does not generally authorize compulsory licenses for any purpose. 57 The full
record of the Stockholm Revision Conference of 1967 makes it clear,
however, that Article 17 was not thought to apply only to censorship, but also
to other necessary powers such as to promote “public order” and control
55

See Berne Convention for the Protection of Literary and Artistic Works art. 9 (2), Sep.
9, 1886, as revised at Paris on July 24, 1971 and amended in 1979, S. Treaty Doc. No. 9927 (1986) ) (“It shall be a matter for legislation in the countries of the Union to permit the
reproduction of such works in certain special cases, provided that such reproduction does not
conflict with a normal exploitation of the work and does not unreasonably prejudice the
legitimate interests of the author.”) (emphasis added).
56
Whether constitutional systems permit administrative action to expand or interpret
copyright limitations and exceptions is beyond the scope of this article.
57
See 1 SAM RICKETSON & JANE C. GINSBURG, INTERNATIONAL COPYRIGHT AND
NEIGHBORING RIGHTS: THE BERNE CONVENTION AND BEYOND 841 (2nd ed. 2006) (arguing
that “[t]he words to permit give rise to two differing interpretations” and rejecting an
interpretation that the provision permits uses outside the limited context of censorship of
works); SILKE VON LEWINSKI, INTERNATIONAL COPYRIGHT LAW AND POLICY 171 (2008)
(“The governmental right to permit, to control, or to prohibit certain acts reflects the ordinary
activity of censorship authorities, which is to decide whether the relevant public order
reasons require the prohibition or other control of the work's circulation.”); PAUL GOLDSTEIN
& BERN HUGENHOLTZ, INTERNATIONAL COPYRIGHT: PRINCIPLES, LAW, AND PRACTICE 37
(4th ed., 2019) (“it seems clear that Article 17 does not constitute authority for the
governmental imposition of compulsory licenses”).
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abuses of monopoly. 58 At least three countries have implemented Article 17
in their legislation, permitting the executive to order the sharing of
copyrighted works to promote critical public interests. 59
Whether through the TRIPS waiver or an interpretation by WIPO or other
bodies, it would be useful to clarify the application of Article 17 as a means
for authorizing uses of works needed during COVID-19. A government
might be able to use the authority to declare that a copyright exception for

58
Together with the proposal for deleting “to permit” from Berne Convention Art. 17,
the United Kingdom also proposed “(document S/171)…(ii) the insertion of a new paragraph
leaving countries free to enact such legislation as is necessary ‘to prevent or deal with any
abuse, by persons or organizations exercising one or more of the rights in a substantial
number of different copyright works, of the monopoly position they enjoy’”. Report on the
Work of Main Committee I (Substantive Provisions of the Berne Convention: Articles 1 to
20), Svante Bergström (Rapporteur) in 2 WIPO, Records of the Intellectual Property
Conference of Stockholm, 1967, at 1174 (1971) (supporting the claim that Article 17 should
not be interpreted as limited to censorship). On this matter, “The Committee accepted,
without opposition, the proposal of its Chairman that mention should be made in this Report
of the fact that questions of public policy should always be a matter for domestic 'legislation
and that the countries of the Union would therefore be able to take all necessary measures to
restrict possible abuse of monopolies. Whereupon, the proposals of Australia and the United
Kingdom relating to abuse of monopoly were withdrawn.”. Id. at 1175
59
See Law No. 65-00 on Aug. 21, 2000, art. 48 [Copyright Act] (Dom. Rep.) (“Prior to
the expiry of the term of protection of a work, the State may order the use, for reasons of
public necessity, of the economic rights in a work that is considered to be of high cultural,
scientific or educational value for the country, or of social or public interest, subject to
payment of fair compensation to the holder of said rights.”); Ley n. 14 de 28 de diciembre
de 1977 de Derecho de Autor, art. 37 [Copyright Act] (Cuba) (“For reasons of social interest,
the competent authority may grant a license to reproduce and publish in printed or other
analogous a work published in the same way, or to translate and edit it, or to broadcast it on
radio, television or other sound or visual media, in its original language or in translation, or
to reproduce in audiovisual form any fixation of the same nature, without the authorization
and remuneration provided in subsections c), ch) and d) of Article 4 of this Law, and provided
that the following conditions are met: a) that the work is necessary for the development of
science, technology, education or professional improvement; b) that its distribution or
dissemination is free of charge or, in the case of sale of printed materials, it is carried out
non-profit; c) that its distribution or diffusion takes place exclusively in the territory of the
Cuban State.”); Ley Federal del Derecho de Autor, publicada en el Diario Oficial de la
Federación el 24 de diciembre de 1996, art. 147 [Copyright law] (Mex.) (“The publication
or translation of literary or artistic works necessary for the advancement of national science,
culture and education is considered of public utility. When it is not possible to obtain the
consent of the owner of the corresponding economic rights, and through the payment of
compensatory remuneration, the Federal Executive, through the Ministry of Culture, ex
officio or at the request of a party, may authorize the mentioned publication or translation.
The foregoing shall be without prejudice to the international treaties on copyright and related
rights signed and approved by Mexico.”).
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uses in the classroom 60 or “on the premises” 61 of a library apply during
COVID to digital extensions of the institution. Or a government might
declare that, during COVID, exceptions for “reproductions” for “research”
should be interpreted to permit text and data mining as well as the reverse
engineering of software needed to repair critical devices. And all countries
should be advised to integrate the Article 17 authority into their laws, as have
Cuba, the Dominican Republic and Mexico. 62
B. Trade Secret Compulsory Licensing
International guidance is also needed to clarify the rights of countries to
compulsory license or otherwise permit the use of trade secrets and know
how. In Brazil, for example, the legislature is considering a draft law on
compulsory licensing that compels patent holders to divulge all “necessary
technical information, including biological materials, to enable the
reproduction of the technology by third parties.” 63 TRIPS does not, however,
provide governments the explicit authority to compel disclosure of trade
secrets. 64 The TRIPS Waiver applied to trade secrets may be the best short
term option for clarifying that international law permits emergency orders to
disclose trade secrets for COVID-19 related treatments and devices. 65

60

See, e.g., Law of Ukraine No. 3792-XII of Dec. 23, 1993, on Copyright and Related
Rights (as amended up to April 26, 2017) art.23 (Ukr.) (“It is allowed without the consent of
the author or another person who has copyright: … 2) reprographic reproduction by
educational institutions for classrooms of published articles and other small-volume works,
as well as excerpts from written works with or without illustrations, provided that: a) the
volume of such reproduction meets the specified purpose; b) the reproduction of the work is
an isolated case and is not systematic;”) (emphasis added)
61
See, e.g., Copyright Act 2018, art. 20 (4) (Act n. 8/2018) (Kiribati) (“A cultural
institution does not infringe copyright in a work in its collection by copying the work for the
purpose of allowing access to that copy by users of the institution whether for personal use
or study on the institution's premises (with or without technical equipment) or by way of a
loan”) (emphasis added).
62
See note 59 above.
63
Medecins Sans Frontieres Access Campaign, Compulsory Licenses, the TRIPS Waiver
and Access to COVID-19 Medical Technologies (MSF Briefing Document, 2021)
https://msfaccess.org/sites/default/files/202105/COVID_TechBrief_MSF_AC_IP_CompulsoryLicensesTRIPSWaiver_ENG_21May20
21_0.pdf. India ordered the release of trade secrets and know how from companies in the
past. See Kasturi Rangan, India Demands ‘Know-How’ and 60% Share of Coca-Cola
NEW
YORK
TIMES
(Aug.
9,
1977),
Operation,
THE
https://www.nytimes.com/1977/08/09/archives/india-demands-knowhow-and-60-share-ofcocacola-operation-company.html (describing Coca-Cola’s cessation of operations in India
in 1977 due to the government’s demand for compulsory transfer of know-how).
64
TRIPS obliges countries to protect trade secrets, Art. 39(2), subject to a right to order
the disclosure of undisclosed data or other information required “as a condition of approving
the marketing of pharmaceutical or of agricultural chemical products” if such disclosure is
“necessary to protect the public.” Art. 39(3). Not all of the needed know how discussed above
may have been submitted to regulatory authorities and therefore may not fall within the
exception in 39(3).
65
Promoting the disclosure of trade secrets could require programs to incentivize
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CONCLUSION
The WTO TRIPS waiver proposal is one example of international action
that can be taken to clarify the flexibilities in international intellectual
property law to address COVID-19. Extending the waiver to the uses of all
intellectual property law needed for vaccines, treatments and containment
measures would clarify that no country could be challenged under the WTO’s
dispute settlement mechanism for actions to permit uses of intellectual
property for the purposes discussed in this Article. Given that the Berne
Convention is incorporated into the TRIPS Agreement, the waiver could
provide a supplementary means of interpreting Berne Article 17.
Alternatively, an agreement or recommendation could be adopted by WIPO
to similar effect. Technical assistance and other projects are also needed to
help countries implement the flexibilities they have, including through
legislative change and emergency regulations authorized by Berne Article 17.

voluntary action as well, for example through buy outs. See James Love, Buying Know-How
to Scale Vaccine Manufacturing, MEDIUM (March 20, 2021) (describing US government
purchase of manufacturing know-how from BioNtech and AstraZeneca’s purchase of knowhow from Oxford University) https://jamie-love.medium.com/buying-know-how-to-scalevaccine-manufacturing-586bdb304a36; Siva Thambisetty et al., The TRIPS Intellectual
Property Waiver Proposal: Creating the Right Incentives in Patent Law and Politics to end
the COVID-19 Pandemic, 6 (LSE Legal Studies Working Paper No. 06-2021) (opining that
“incentives (‘carrots’) for voluntary disclosures” “may be more palatable, politically”),
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3851737. Commitments to share know
how and trade secrets can be included in government funding contracts, for example.
Garrison, supra note 40; Pascale Boulet et al., Advanced Purchase Agreements for COVID19 Vaccines: Analysis and Comments, MEDICINES LAW & POLICY (Juj. 2021) (criticizing
lack of disclosure requirements in funding contracts from western governments),
https://left.eu/content/uploads/2021/07/Advanced-purchase-agreements-1.pdf..
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